GFM
GF Fund Management Portfolio holdings
AUM
$4.97B
This Quarter Return
+7.58%
1 Year Return
–
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$4.62B
AUM Growth
–
Cap. Flow
+$4.62B
Cap. Flow
% of AUM
100%
Top 10 Holdings %
Top 10 Hldgs %
48.03%
Holding
637
New
637
Increased
–
Reduced
–
Closed
–
Top Buys
| 1 |
NVIDIA
NVDA
|
$390M |
| 2 |
Apple
AAPL
|
$374M |
| 3 |
Microsoft
MSFT
|
$322M |
| 4 |
Amazon
AMZN
|
$234M |
| 5 |
Meta Platforms (Facebook)
META
|
$194M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Technology | 45.53% |
| 2 | Consumer Discretionary | 17.29% |
| 3 | Communication Services | 14.35% |
| 4 | Healthcare | 6.6% |
| 5 | Consumer Staples | 4.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
426
DiamondRock Hospitality
DRH
$1.76B
| $34K | ﹤0.01% |
+3,766
| New | +$34K |
|
427
Structure Therapeutics
GPCR
$1.27B
| $33.9K | ﹤0.01% |
+1,251
| New | +$33.9K |
|
428
Xencor
XNCR
$610M
| $33.8K | ﹤0.01% |
+1,469
| New | +$33.8K |
|
429
BioCryst Pharmaceuticals
BCRX
$1.74B
| $32.7K | ﹤0.01% |
+4,349
| New | +$32.7K |
|
430
10x Genomics
TXG
$1.74B
| $32.3K | ﹤0.01% |
+2,247
| New | +$32.3K |
|
431
Travere Therapeutics
TVTX
$1.93B
| $31.4K | ﹤0.01% |
+1,803
| New | +$31.4K |
|
|
CNTA
432
Centessa Pharmaceuticals
CNTA
$2.11B
| $31.4K | ﹤0.01% |
+1,872
| New | +$31.4K |
|
433
Praxis Precision Medicines
PRAX
$986M
| $30.1K | ﹤0.01% |
+391
| New | +$30.1K |
|
434
Pebblebrook Hotel Trust
PEB
$1.4B
| $29.7K | ﹤0.01% |
+2,190
| New | +$29.7K |
|
435
RLJ Lodging Trust
RLJ
$1.18B
| $28.8K | ﹤0.01% |
+2,817
| New | +$28.8K |
|
436
Spyre Therapeutics
SYRE
$1.03B
| $28.7K | ﹤0.01% |
+1,232
| New | +$28.7K |
|
437
Zai Lab
ZLAB
$3.42B
| $28.7K | ﹤0.01% |
+1,095
| New | +$28.7K |
|
438
Ocular Therapeutix
OCUL
$2.37B
| $28.2K | ﹤0.01% |
+3,301
| New | +$28.2K |
|
|
GTY
439
Getty Realty Corp
GTY
$1.63B
| $28.2K | ﹤0.01% |
+935
| New | +$28.2K |
|
440
Nurix Therapeutics
NRIX
$758M
| $28K | ﹤0.01% |
+1,487
| New | +$28K |
|
441
Arvinas
ARVN
$575M
| $27.7K | ﹤0.01% |
+1,443
| New | +$27.7K |
|
|
XHR
442
Xenia Hotels & Resorts
XHR
$1.38B
| $27.5K | ﹤0.01% |
+1,853
| New | +$27.5K |
|
|
LTC
443
LTC Properties
LTC
$1.69B
| $27.3K | ﹤0.01% |
+790
| New | +$27.3K |
|
444
Novavax
NVAX
$1.28B
| $27K | ﹤0.01% |
+3,363
| New | +$27K |
|
445
Aurinia Pharmaceuticals
AUPH
$1.63B
| $27K | ﹤0.01% |
+3,006
| New | +$27K |
|
446
Day One Biopharmaceuticals
DAWN
$773M
| $26.8K | ﹤0.01% |
+2,117
| New | +$26.8K |
|
447
Empire State Realty Trust
ESRT
$1.35B
| $26.4K | ﹤0.01% |
+2,557
| New | +$26.4K |
|
448
Global Net Lease
GNL
$1.77B
| $26K | ﹤0.01% |
+3,560
| New | +$26K |
|
|
UMH
449
UMH Properties
UMH
$1.29B
| $25.6K | ﹤0.01% |
+1,356
| New | +$25.6K |
|
450
Ardelyx
ARDX
$1.57B
| $25.2K | ﹤0.01% |
+4,973
| New | +$25.2K |
|